BLUE BELL, Pa.
Feb. 28, 2012
/PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO) announced today that Inovio management will present an overview of the company at investment conferences hosted by Cowen Group and ROTH Capital Partners.
Cowen 32nd Annual Health Care Conference
110 Huntington Ave, The Boston Marriott Copley Place
Monday, March 5
3:30 - 4:00 p.m. EST
J. Joseph Kim
, PhD, President and CEO
A live and archived webcast of the presentation will be accessible on Inovio's website at
ROTH 24th Annual Conference
Dana Point, CA
1 Ritz Carlton Dr, The Ritz Carlton
Wednesday, March 14
11:30 - 12:00 p.m. PST
About Inovio Pharmaceuticals, Inc.
Inovio is revolutionizing vaccines to prevent and treat today's cancers and challenging infectious diseases. Its SynCon® vaccines are designed to provide universal cross-strain protection against known as well as newly emergent unmatched strains of pathogens such as influenza. These synthetic vaccines, in combination with Inovio's proprietary electroporation delivery, have been shown in humans to generate best-in-class immune responses with a favorable safety profile. Inovio's clinical programs include Phase II studies for cervical dysplasia, leukemia and hepatitis C virus and Phase I studies for influenza and HIV. Partners and collaborators include the
University of Pennsylvania
, Merck, ChronTech, National Cancer Institute, U.S. Military HIV Research Program, NIH, HIV Vaccines Trial Network, University of Southampton, US Dept. of Homeland Security and PATH Malaria Vaccine Initiative. More information is available at
* * *